Background: Following heart transplantation (HT), HMG CoA reductase inhibitors (statins) have been shown to reduce total and low-density lipoprotein (LDL) cholesterol, development of cardiac allograft vasculopathy (CAV), and mortality. Studies in HT patients have demonstrated the safety of low/moderate intensity statins; however, little data exist using high-intensity (HI) statins. The study aim was to evaluate the safety and efficacy of HI statins in HT recipients receiving tacrolimus. Results: Among the 24 patients included, one experienced myalgias and therapy discontinuation (4%; P > 0.99). No other HI statin dose reduction/discontinuation occurred, and no instances of rhabdomyolysis or hepatotoxicity were observed. The average reduction in total and LDL cholesterol after conversion to HI statin was 35 mg/dL (P = 0.02) and 19 mg/dL (P = 0.10), respectively.
| INTRODUC TI ON
Following heart transplantation (HT), HMG CoA reductase inhibitors (statins) have been shown to reduce total and low-density lipoprotein (LDL) cholesterol, development of cardiac allograft vasculopathy (CAV), and mortality. [1] [2] [3] [4] [5] As a result, The International Society for Heart and Lung Transplantation (ISHLT) gives a Class I, Level of Evidence A recommendation to the initiation of statin therapy in all adult patients 1-2 weeks posttransplantation, regardless of cholesterol levels. 6 Several studies in HT patients have demonstrated the safety and efficacy of moderate-intensity statins, specifically pravastatin and simvastatin. [1] [2] [3] [4] [5] The American College of Cardiology and American Heart Association define low-, moderate-, and high-intensity (HI) statins as agents which lower LDL cholesterol on average by <30%, 30%-50%, and >50%, respectively. Atorvastatin at doses of 40-80 mg/d and rosuvastatin at doses of 20-40 mg/d are the only available HI statin options. 7 In nontransplant patients, atorvastatin, at doses between 40 and 80 mg/d, has demonstrated superior efficacy in LDL reduction and prevention of cardiovascular events over moderate-and low-intensity statin regimens. 8 Given that hyperlipidemia is a potential risk factor for CAV, it can be theorized that regimens with greater lipid reduction potential may provide additional benefit for HT patients. Furthermore, statins are known to have immunomodulatory effects. One mechanism by which statins may reduce host immune response is through a reduction in the expression of major histocompatibility complex (MHC) class II molecules, impairing the presentation of antigens to T lymphocytes. Statin administration has also been shown to lead to reduced plasma monocyte concentrations. Given that both T lymphocytes and monocytes play a role in the graft rejection process, the reduced activity of these immune cells may promote vasculoprotection. 9 It is therefore hypothesized that reduced rates of CAV occur via both treatment of hyperlipidemia and reduction in immune response.
Despite the benefit of HI statin regimens in nontransplant patients, the above-mentioned ISHLT guidelines recommend HT patients receive doses lower than those recommended for hyperlipidemia due to potential pharmacologic interactions with calcineurin inhibitors. 6 Calcineurin inhibitors, as substrates for CYP3A4
and several membrane transporters, have the potential to increase systemic exposure to statins and lead to an increased risk of myopathy and rhabdomyolysis. 10, 11 Pharmacokinetic studies have demonstrated that administration of cyclosporine with atorvastatin may increase atorvastatin AUC by 6-to 15-fold. 10 This interaction is attributed to the inhibition of CYP3A4 and several transporters by cyclosporine, impairing atorvastatin metabolism and increasing serum atorvastatin concentrations. 10 Administration of cyclosporine with rosuvastatin has resulted in a 7.1-fold increase in AUC of rosuvastatin, which is thought to be due to cyclosporine's inhibition of the hepatic transporter, organic anion transporting polypeptide C (OATP-C). Inhibition of OATP-C impairs cellular uptake of rosuvas- 
| MATERIAL S & ME THODS

| Study design
We conducted a single-center, retrospective review of all adult tacrolimus-treated HT recipients at our institution from January 1, 
| Study outcomes & data analysis
We hypothesized that the risk of adverse events or intolerance with the use of HI statins would be no greater than the risk with a currently tolerated low-to-moderate intensity statin. The primary outcome, tolerability, was defined as absence of new myalgia, rhabdomyolysis, hepatotoxicity, or any statin dose reduction or discontinuation due to adverse drug events assessed throughout the 6 months after conversion from low-to-moderate intensity to HI statin therapy. Myalgia was defined as symptoms of muscle soreness without creatinine kinase (CK) elevation, rhabdomyolysis was defined as an elevation of CK >10 times the upper limit of normal (ULN), and hepatotoxicity was defined as the elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than or equal to three times the ULN.
The secondary outcome, assessing efficacy, was the reduction in total and LDL cholesterol from baseline (while on low-to-moderate intensity statin) to 6 months after conversion to HI statin. 
| RE SULTS
| Baseline characteristics
A total of 153 heart transplants performed during the study period were assessed for inclusion. A total of 129 patients were excluded, leaving 24 patients to be analyzed ( Figure 1 ). The statin therapy initiated post-HT was pravastatin 40 mg daily (18, 75%), pravastatin 20 mg daily (3, 13%), pravastatin 10 mg daily (2, 8%), and simvastatin 20 mg daily (1, 4%). The majority of the study population were middle-aged men with nonischemic heart failure ( Table 1) .
| Time of conversion to HI statin
Twenty-three patients were converted to atorvastatin and one patient was converted to rosuvastatin. The indications for conversion to HI statin therapy were primarily persistent hyperlipidemia (68%) and development of CAV (16%). Some patients were converted to a more affordable regimen (4%), which was incidentally a HI statin. 
| Safety and efficacy at 6 months
Among the 24 patients included, one patient (4%; P > 0.99) experienced myalgias (and drug discontinuation) after conversion to HI statin. No instances of rhabdomyolysis or significant changes in hepatic transaminases were identified. No dose reductions were required within 6 months postconversion. The average reduction in total and LDL cholesterol during the follow-up period was 35 mg/dL (P = 0.02) and 19 mg/dL (P = 0.10), respectively ( Table 2) .
One patient experienced myalgias prior to conversion to HI statin; however, there was clear documentation that this adverse effect was due to colchicine. Symptoms resolved with colchicine discontinuation.
| D ISCUSS I ON
To our knowledge, this is the first study assessing the safety of HI Myalgias occurred infrequently and resolved quickly after drug discontinuation.
We identified 6 months as an appropriate follow-up period to allow adequate time to assess for both durable tolerance of HI statin and changes in lipid levels. While it is certainly possible for patients to experience adverse effects at any time point during statin therapy, similar studies reported that the majority of adverse events occurred within the first 4 months.
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F I G U R E 1 Inclusion and exclusion criteria 
| Statin-induced adverse events
Our rates of reported adverse effects due to HI statins taken concurrently with tacrolimus were not substantially higher than those in trials studying nontransplant patients. In an analysis of 17 placebo- We noted one patient who experienced myalgias, leading to discontinuation of the HI statin within 6 months after conversion from a moderate-intensity statin. The patient was converted to atorvastatin 80 mg daily due to persistent hyperlipidemia and was also taking diltiazem extended release 180 mg daily at the time of conversion. Six months after starting the HI statin, the patient was seen in two emergency departments within 24 hours for complaints of right-sided chest pain, back pain, and diffuse muscle cramping.
The patient's CK was elevated to 325 U/L. The decision was made to discontinue the HI statin, and 1 month later the patient reported resolution of myalgias.
Three patients diagnosed with CAV died within 1 month after converting to a HI statin. The first patient underwent placement of multiple coronary stents and was converted to atorvastatin 80 mg.
Two weeks later, the patient was admitted for hematochezia with a hemoglobin nadir of 6.6 g/dL. He was scheduled for an endoscopy and died after a pulseless electrical activity arrest. Transesophageal echocardiogram during emergency resuscitation indicated thrombi in the right and left ventricles which extended into the aorta. Autopsy revealed cause of death to be cardiopulmonary collapse secondary to acute hypoxic respiratory failure. A second patient was converted to atorvastatin 80 mg after a new diagnosis of CAV. She was found deceased at home 25 days after conversion to HI statin. A limited autopsy identified the immediate cause of death to be CAV. Finally, the third patient was converted to atorvastatin 40 mg during a hospital admission for left ventricular thrombus. Twenty-three days after the switch, the patient was found deceased at home after reports of multiple days of increasing edema and refusal to seek medical attention. Autopsy was not performed on this patient. All three patients were excluded from our analysis due to incomplete follow-up data;
however, given the nature of each inciting event, we believe that none of the above occurrences are attributable to HI statin initiation.
| Potential for CAV reduction
Cardiac allograft vasculopathy, a complication of HT, continues to impact the long-term success rates of heart transplants. Despite new 
| Study limitations
Our study has several important limitations. First, it is limited by the inherent biases of a retrospective, single-center design. Additionally, our sample size, while reflective of the frequency of hyperlipidemia or CAV in a larger sample of HT patients, is relatively small. Since ours is the only study assessing the use of HI statins in HT patients to date, more data are needed to definitively conclude that this practice is truly safe and effective across a broad HT patient population. In addition, few patients in our small sample went on to develop CAV, so reductions in LDL and total cholesterol were utilized as surrogate efficacy outcomes. Larger, prospective studies are necessary to assess the effect of high-intensity statin therapy on CAV outcomes.
Furthermore, given the differences in common practice in the previous decade, C-reactive protein (CRP) was not routinely measured in the study population, and only one HI statin patient was prescribed rosuvastatin. It is therefore difficult to draw conclusions about potential immunomodulatory effects of HI statins or the safety of rosuvastatin in this population and further studies are needed.
It is also important that future studies assess the safety of using a HI statin closer to time of HT. The median tacrolimus level of our study population was 7.2 ng/mL; however, the goal tacrolimus level early post-HT is often 10-15 ng/mL. Therefore, if the interaction between HI statins and tacrolimus is dose-dependent, tolerance rates may differ immediately following transplantation.
Finally, study subjects were only included if they previously tolerated a low-to-moderate intensity statin. The purpose of selecting patients who had tolerated previous statin therapy was so that each individual could serve as their own control in statistical analysis. Our data do not address the statin tolerability of patients who have not been previously exposed to statin therapy.
| CON CLUS IONS
Managing hyperlipidemia and CAV after HT can be challenging due to potential drug interactions between immunosuppressive agents and statins. In our limited patient cohort, HI statin therapy was safe and efficacious in HT recipients receiving tacrolimus, with no patients experiencing hepatotoxicity or rhabdomyolysis. Treatment with a HI statin can be considered a reasonable option for hyperlipidemia refractory to moderate-or low-intensity statins. Further prospective studies are needed to confirm the safety and efficacy of HI statins in a larger study population, specifically addressing CAV outcomes.
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